Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241527 · ClinicalTrials.gov registry record · Phase 3
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 556
- Enrollment target
NCT00241527 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 556 participants.
The verdict
NCT00241527, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 556 participants
- Enrollment target
Study Summary
This study was a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs placebo and esomeprazole 20 mg orally qd vs placebo when given to patients on continuous use of NSAIDs, including COX-2 selective NSAIDs, for a treatment period of 4 weeks for relief of upper GI symptoms.
Interventions
- DRUG Esomeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 556 participants |
| Start Date | 2000-12 |
| Est. Completion | 2002-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00241527
The ClinicalTrials.gov registry entry for NCT00241527 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 556 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Esomeprazole is the first listed.
NCT00241527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00241527 about?
NCT00241527 is a clinical study titled "Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs". This study was a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs placebo and esomeprazole 20 mg orally qd vs placebo when given to patients on continuous use of NSAIDs, including COX-2 selective NSAIDs, for a treatment p...
What is the current status of trial NCT00241527?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 556 participants. The study started on 2000-12. Estimated completion is 2002-09.
What interventions are being tested in trial NCT00241527?
The interventions under investigation include: Esomeprazole (DRUG).
Who is sponsoring clinical trial NCT00241527?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.